Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease☆
暂无分享,去创建一个
Nikolaus Weiskopf | Nico Bunzeck | Emrah Düzel | Masud Husain | Richard J. Perry | Peter G. Bain | Victoria Singh-Curry | M. Husain | N. Bunzeck | E. Düzel | N. Weiskopf | P. Bain | R. Perry | V. Singh-Curry | Cindy Eckart | Cindy Eckart
[1] O. Hornykiewicz,et al. Globus pallidus dopamine and Parkinson motor subtypes , 2008, Neurology.
[2] Regina Katzenschlager,et al. Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome , 2004, Movement disorders : official journal of the Movement Disorder Society.
[3] Moussa B. H. Youdim,et al. Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity , 2010, Progress in Neurobiology.
[4] I. McKeith,et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[5] Anders M. Dale,et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: The effects of field strength, scanner upgrade and manufacturer , 2006, NeuroImage.
[6] E. Oberhauser,et al. Iron concentratio n bal ganglia and cerebral cortex obtained by overloading rabbits and monkeys with iron dextran. , 1970, Journal of neurosurgery.
[7] R. Balaban,et al. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo , 1989, Magnetic resonance in medicine.
[8] Richard S. Frackowiak,et al. Improved segmentation of deep brain grey matter structures using magnetization transfer (MT) parameter maps , 2009, NeuroImage.
[9] Marguerite Wieler,et al. Midbrain iron content in early Parkinson disease , 2008, Neurology.
[10] Klaus Seppi,et al. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism , 2005, Current opinion in neurology.
[11] J. Missimer,et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. , 1995, Archives of neurology.
[12] B. Bergamasco,et al. Modifications of the iron–neuromelanin system in Parkinson's disease , 2006, Journal of neurochemistry.
[13] K J Rothman,et al. No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.
[14] J. Connor,et al. Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.
[15] A. Stefani,et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. , 2010, Brain : a journal of neurology.
[16] Ronald J. Faber,et al. Compulsive buying: descriptive characteristics and psychiatric comorbidity. , 1994, The Journal of clinical psychiatry.
[17] Mircea Ariel Schoenfeld,et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging , 2004, NeuroImage.
[18] S. Chung,et al. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease , 2008, Movement Disorders.
[19] Richard S. Frackowiak,et al. Regional specificity of MRI contrast parameter changes in normal ageing revealed by voxel-based quantification (VBQ) , 2011, NeuroImage.
[20] J. Jankovic,et al. Functional decline in Parkinson disease. , 2001, Archives of neurology.
[21] Beate Ritz,et al. Clinical characteristics in early Parkinson's disease in a central California population‐based study , 2005, Movement disorders : official journal of the Movement Disorder Society.
[22] Robin K. Henson,et al. The Use and Impact of Adjusted R 2 Effects in Published Regression Research , 2007 .
[23] D. Koziorowski,et al. Iron as a cause of Parkinson disease - a myth or a well established hypothesis? , 2009, Parkinsonism & related disorders.
[24] A. Lees,et al. A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.
[25] T Revesz,et al. A clinico-pathological study of subtypes in Parkinson's disease. , 2009, Brain : a journal of neurology.
[26] Hans-Jochen Heinze,et al. Mesolimbic novelty processing in older adults. , 2007, Cerebral cortex.
[27] M. Farrer,et al. Missing pieces in the Parkinson's disease puzzle , 2010, Nature Medicine.
[28] Anders M. Dale,et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths , 2009, NeuroImage.
[29] D. Aarsland,et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[30] Peter Riederer,et al. The relevance of iron in the pathogenesis of Parkinson’s disease , 2011, Journal of neurochemistry.
[31] K. Jellinger,et al. The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.
[32] Junxia Xie,et al. Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson’s disease , 2011, Journal of Neural Transmission.